Treatment

Herceptin 150 mg powder for concentrate for solution for infusion clinical trials

3 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)
This study is looking at new ways to treat early-stage breast cancer before standard surgery. It's for people with specific types of breast cancer (triple-negative or HER2+). Researchers are testing if certain immune-boosting medicines can help the body fight the cancer better, hoping to improve treatment outcomes.
For: Newly diagnosed · non-metastatic early-stage triple-negative or HER2+ breast cancer
France
Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A phase Ib study of Ipatasertib, an AKT inhibitor, in combination with Pertuzumab plus Trastuzumab in patients with PIK3CA-mutant, HER2-positive locally advanced or metastatic breast cancer.
This study looks at a new drug, ipatasertib, combined with standard treatments (Herceptin and Perjeta) for a specific type of advanced breast cancer. It aims to find the safest and most effective dose of ipatasertib for patients whose cancer has a particular genetic change (PIK3CA mutant) and a lot of HER2 protein.
For: Patients with PIK3CA-mutant · HER2-positive locally advanced or metastatic breast cancer · candidates to receive maintenance therapy with trastuzumab plus pertuzumab (HP) after first line treatment for metastatic disease with a taxane or vinorelbine plus HP.
Spain
Ongoing, recruitingTherapeutic exploratory (Phase II)
C4251003- A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations.
This study is looking at a new combination of medicines for people with certain advanced cancers where previous treatments haven't worked well. It aims to see how many people respond to the treatment.
For: Previously Treated · Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Germany · Belgium · Spain

Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)

A phase Ib study of Ipatasertib, an AKT inhibitor, in combination with Pertuzumab plus Trastuzumab in patients with PIK3CA-mutant, HER2-positive locally advanced or metastatic breast cancer.

C4251003- A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations.